评估人工智能辅助前列腺双参数MRI判读:一项国际多读者研究
这项回顾性、多读者、多中心研究纳入180例患者,6名不同经验放射科医生在有和无AI辅助下判读bpMRI。AI辅助提高了病灶水平PPV和读者间一致性,但降低了病灶水平敏感度,患者水平AUC无差异。
要点
- AI辅助提高病灶水平PPV(PI-RADS≥3:csPCa 77.2% vs 67.2%,PCa 80.9% vs 69.4%)。
- AI辅助降低病灶水平敏感度(PI-RADS≥3:csPCa 44.4% vs 48.0%,PCa 41.7% vs 44.9%)。
- AI辅助提高病灶水平PI-RADS评分读者间一致性(κ=0.748 vs 0.336)。
核心结论
- AI辅助提高了病灶水平PPV和读者间一致性,但病灶水平敏感度略有降低;患者水平AUC无差异。
研究设计与样本
- 回顾性、多读者、多中心研究,采用平衡不完全区组设计随机分配MRI,共180例患者(病例组120例,对照组60例),6名不同经验放射科医生在有和无AI辅助下交替判读bpMRI;病灶水平参考标准为根治性前列腺切除术后全mount病理,对照患者为阴性12针系统活检。
诊断标准与关键数值
- 病灶水平PPV(PI-RADS≥3):csPCa AI辅助77.2%(95%CI 71.0-83.1%)vs 无AI 67.2%(95%CI 61.1-72.2%),p<.001;PCa AI辅助80.9%(95%CI 75.2-85.7%)vs 无AI 69.4%(95%CI 63.4-74.1%),p<.001。
- 病灶水平敏感度(PI-RADS≥3):csPCa AI辅助44.4%(95%CI 38.6-50.5%)vs 无AI 48.0%(95%CI 42.0-54.2%),p=.01;PCa AI辅助41.7%(95%CI 37.0-47.4%)vs 无AI 44.9%(95%CI 40.5-50.2%),p=.01。
- 患者水平AUC:csPCa AI辅助0.822(95%CI 0.768-0.866)vs 无AI 0.832(95%CI 0.787-0.868),p=.61;PCa AI辅助0.833(95%CI 0.782-0.874)vs 无AI 0.835(95%CI 0.792-0.871),p=.91。
- 病灶水平PI-RADS评分读者间一致性:AI辅助κ=0.748(95%CI 0.701-0.796)vs 无AI κ=0.336(95%CI 0.288-0.381),p<.001。
- 病灶大小测量读者间一致性:AI辅助覆盖概率0.397(95%CI 0.376-0.419)vs 无AI 0.367(95%CI 0.349-0.383),p<.001;患者水平PI-RADS评分读者间一致性:AI辅助κ=0.704(95%CI 0.627-0.767)vs 无AI κ=0.507(95%CI 0.421-0.584),p<.001。
临床应用与阅片要点
- AI辅助可能提高bpMRI判读的一致性和减少假阳性。
- 需进一步优化以提高敏感度而不牺牲特异度。
局限性
- 需进一步优化以提高敏感度而不牺牲特异度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Variability in prostate biparametric MRI (bpMRI) interpretation limits diagnostic reliability for prostate cancer (PCa). Artificial intelligence (AI) has the potential to reduce this variability and improve diagnostic accuracy. OBJECTIVE. The objective of this study was to evaluate the impact of a deep learning AI model on lesion- and patient-level rates of detection of PCa and clinically significant PCa (csPCa) and interreader agreement for bpMRI interpretations. METHODS. This retrospective, multireader, multicenter study used a balanced incomplete block design for MRI randomization. Six radiologists of varying experience interpreted bpMRI scans with and without AI assistance in alternating sessions. The reference standard for lesion-level detection for cases was whole-mount pathology after radical prostatectomy; for control patients, it was negative 12-core systematic biopsies. In all, 180 patients (120 in the case group and 60 in the control group) who underwent mpMRI and prostate biopsy or radical prostatectomy between January 2013 and December 2022 were included. Lesion-level sensitivity, PPV, and patient-level AUC for csPCa and PCa detection and interreader agreement for lesion-level PI-RADS scores and size measurements were assessed. RESULTS. AI assistance improved lesion-level PPV (PI-RADS ≥ 3: 77.2% [95% CI, 71.0-83.1%] vs 67.2% [95% CI, 61.1-72.2%] for csPCa; 80.9% [75.2-85.7%] vs 69.4% [95% CI, 63.4-74.1%] for PCa; both p < .001), reduced lesion-level sensitivity (PI-RADS ≥ 3: 44.4% [95% CI, 38.6-50.5%] vs 48.0% [95% CI, 42.0-54.2%] for csPCa; p = .01; 41.7% [95% CI, 37.0-47.4%] vs 44.9% [95% CI, 40.5-50.2%] for PCa; p = .01), and no difference in patient-level AUC (0.822 [95% CI, 0.768-0.866] vs 0.832 [95% CI, 0.787-0.868] for csPCa; p = .61; 0.833 [0.782-0.874] vs 0.835 [95% CI, 0.792-0.871] for PCa; p = .91). AI assistance improved interreader agreement for lesion-level PI-RADS scores (κ = 0.748 [95% CI, 0.701-0.796] vs 0.336 [95% CI, 0.288-0.381]; p < .001), lesion size measurements (coverage probability of 0.397 [95% CI, 0.376-0.419] vs 0.367 [95% CI, 0.349-0.383]; p < .001), and patient-level PI-RADS scores (κ = 0.704 [95% CI, 0.627-0.767] vs 0.507 [95% CI, 0.421-0.584]; p < .001). CONCLUSION. AI improved lesion-level PPV and interreader agreement with slightly lower lesion-level sensitivity. CLINICAL IMPACT. AI may enhance consistency and reduce false-positives in bpMRI interpretations. Further optimization is required to improve sensitivity without compromising specificity.
引用
- Gelikman DG, Yilmaz EC, Harmon SA, et al. Evaluating Artificial Intelligence-Assisted Prostate Biparametric MRI Interpretation: An International Multireader Study. AJR Am J Roentgenol. 2025. PMID: 40668633. doi:10.2214/AJR.24.32399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。